Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.

Abstract

Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.

• Authors: Yun-Hong Cheon, Moon Jin Kim, Min Gyu Kang, Hee Jin Kim, Sang Su Lee, Cha Young Kim, Dae-Hong Jeon, Yu Eun Kim, Gyeong-Won Lee
• Journal: Yonsei medical journal (Yonsei Med J) Vol. 52 Issue 4 Pg. 695-8 (Jul 2011) ISSN: 1976-2437 [Electronic] Korea (South)
• PMID: 21623617 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Quinazolines
• Erlotinib Hydrochloride

Topics

• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (complications, drug therapy)
• Erlotinib Hydrochloride
• Female
• Humans
• Intestinal Fistula (chemically induced, complications, diagnostic imaging, surgery)
• Intestinal Perforation (chemically induced, complications, diagnostic imaging, surgery)
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Quinazolines (adverse effects, therapeutic use)
• Radiography
• Sigmoid Diseases (chemically induced, complications, diagnostic imaging, surgery)